| Dr Jeffrey M Stewart, MD | |
|
185 Rykowski Ln, Middletown, NY 10941-4055 | |
| (845) 703-6999 | |
| (845) 703-6297 |
| Full Name | Dr Jeffrey M Stewart |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 36 Years |
| Location | 185 Rykowski Ln, Middletown, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982715892 | NPI | - | NPPES |
| 01524065 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 195350 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of Orange & Sullivan Counties Inc | Newburgh, NY | Hospice |
| Garnet Health Medical Center | Middletown, NY | Hospital |
| Garnet Health Medical Center Catskills | Harris, NY | Hospital |
| Bon Secours Community Hospital | Port jervis, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crystal Run Healthcare Physicians Llp | 6901792696 | 395 |
News Archive
An anti-abortion group challenged an Ohio law banning false statements by political campaigns. The Ohio law makes it illegal to knowingly or recklessly make false statements about a candidate during an election. ...
Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
During the "Novel Implications for Blood Flow and Vascular Dysfunction in Non-cardiovascular Related Disease" symposium at the APS Cardiovascular Aging: New Frontiers and Old Friends conference, researchers will present findings that emphasize the interaction between age-related cardiovascular dysfunction and disease whose risk increases with age.
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.
› Verified 2 days ago
| Entity Name | Crystal Run Healthcare Physicians Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952376410 PECOS PAC ID: 6901792696 Enrollment ID: O20040227000791 |
News Archive
An anti-abortion group challenged an Ohio law banning false statements by political campaigns. The Ohio law makes it illegal to knowingly or recklessly make false statements about a candidate during an election. ...
Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
During the "Novel Implications for Blood Flow and Vascular Dysfunction in Non-cardiovascular Related Disease" symposium at the APS Cardiovascular Aging: New Frontiers and Old Friends conference, researchers will present findings that emphasize the interaction between age-related cardiovascular dysfunction and disease whose risk increases with age.
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey M Stewart, MD 155 Crystal Run Rd, Middletown, NY 10941-4028 Ph: (845) 703-6999 | Dr Jeffrey M Stewart, MD 185 Rykowski Ln, Middletown, NY 10941-4055 Ph: (845) 703-6999 |
News Archive
An anti-abortion group challenged an Ohio law banning false statements by political campaigns. The Ohio law makes it illegal to knowingly or recklessly make false statements about a candidate during an election. ...
Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).
During the "Novel Implications for Blood Flow and Vascular Dysfunction in Non-cardiovascular Related Disease" symposium at the APS Cardiovascular Aging: New Frontiers and Old Friends conference, researchers will present findings that emphasize the interaction between age-related cardiovascular dysfunction and disease whose risk increases with age.
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Use for 2 or more years of proton pump inhibitors and histamine 2 receptor antagonists (two types of acid-inhibiting medications) was associated with a subsequent new diagnosis of vitamin B12 deficiency, according to a study appearing in the December 11 issue of JAMA.
› Verified 2 days ago
Dr. Aamir Masood Gilani, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 707 E Main St, Middletown, NY 10940 Phone: 845-333-7575 Fax: 845-333-7202 | |
Dr. Dahlia Banerji, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 111 Maltese Dr, Middletown, NY 10940 Phone: 845-342-4774 | |
Rafeel O Syed, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 155 Crystal Run Rd, Middletown, NY 10941 Phone: 845-703-6999 Fax: 845-703-6297 | |
Nancy I. Linneman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 155 Crystal Run Rd, Middletown, NY 10941 Phone: 845-703-6999 Fax: 845-703-6297 | |
Dr. Corina Cristescu, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 111 Maltese Dr, Middletown, NY 10940 Phone: 845-342-4774 Fax: 845-818-7555 | |
Dr. Robert Lewis Douglas, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 210 E Main St, Middletown, NY 10940 Phone: 845-342-5681 Fax: 845-342-0470 | |
Peggy Nelson, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 155 Crystal Run Rd, Middletown, NY 10941 Phone: 845-703-6999 Fax: 845-703-6297 |